HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and binzoxazinorifamycin, KRM-1648, in human liver microsomes
HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and binzoxazinorifamycin, KRM-1648, in human liver microsomes
复制标题
DOI：
10.1016/s0378-4274(97)00098-2
复制
发表时间：
1997-12-01
影响因子：
3.5
通讯作者：
Hidaka, T
中科院分区：
文献类型：
--
作者：
Inaba, T;Fischer, NE;Hidaka, T
蛋白酶抑制剂利托那韦、茚地那韦和沙奎那韦是迄今为止开发的最有效的抗HIV药物，它们通过竞争CYP3A4与许多药物相互作用，CYP3A4是多种化合物代谢的核心酶。使用人肝微粒体来比较这三种蛋白酶抑制剂的抑制作用。利托那韦和茚地那韦的抑制作用最大，沙奎那韦的抑制作用较弱。(C)1997 Elsevier Science爱尔兰有限公司
The protease inhibitors, ritonavir, indinavir and saquinavir, the most potent anti-HIV drugs developed to date, interact with many drugs by competing for CYP3A4, an enzyme central to the metabolism of a wide variety of compounds. Human liver microsomes were used to compare inhibition by these three protease inhibitors. The inhibition was the greatest with ritonavir and indinavir and less potent with saquinavir. (C) 1997 Elsevier Science Ireland Ltd.